From GWAS to clinical utility in Parkinson's disease

Lancet. 2011 Feb 19;377(9766):613-4. doi: 10.1016/S0140-6736(11)60062-7. Epub 2011 Feb 1.

Authors

Christine Klein¹, Andreas Ziegler

Affiliation

¹ Section of Clinical and Molecular Neurogenetics, Department of Neurology, University of Lübeck, 23538 Lübeck, Germany. christine.klein@neuro.uni-luebeck.de

PMID: 21292316
DOI: 10.1016/S0140-6736(11)60062-7

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Genetic Diseases, Inborn / genetics
Genetic Predisposition to Disease / genetics*
Genetic Privacy / ethics
Genetic Testing / ethics
Genome-Wide Association Study*
Humans
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Parkinson Disease / genetics*
Polymorphism, Single Nucleotide / genetics
Protein-Serine-Threonine Kinases / genetics
Risk Assessment
alpha-Synuclein / genetics

Substances

SNCA protein, human
alpha-Synuclein
LRRK2 protein, human
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Protein-Serine-Threonine Kinases